etomoxir has been researched along with orlistat in 3 studies
| Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (orlistat) | Trials (orlistat) | Recent Studies (post-2010) (orlistat) |
|---|---|---|---|---|---|
| 260 | 8 | 93 | 1,432 | 274 | 539 |
| Protein | Taxonomy | etomoxir (IC50) | orlistat (IC50) |
|---|---|---|---|
| Phosphatidylserine lipase ABHD16A | Homo sapiens (human) | 0.1 | |
| Pancreatic triacylglycerol lipase | Sus scrofa (pig) | 0.4214 | |
| Lipoprotein lipase | Homo sapiens (human) | 0.066 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.42 | |
| Hepatic triacylglycerol lipase | Homo sapiens (human) | 0.003 | |
| Pancreatic triacylglycerol lipase | Homo sapiens (human) | 0.3253 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 1 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.42 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.1903 | |
| Fatty acid synthase | Homo sapiens (human) | 2.99 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.01 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.05 | |
| Diacylglycerol lipase-alpha | Mus musculus (house mouse) | 0.02 | |
| Lysophosphatidylserine lipase ABHD12 | Homo sapiens (human) | 0.1682 | |
| Diacylglycerol lipase-beta | Homo sapiens (human) | 0.24 | |
| Monoacylglycerol lipase ABHD6 | Homo sapiens (human) | 0.03 | |
| Acyl-protein thioesterase 2 | Rattus norvegicus (Norway rat) | 0.17 | |
| Diacylglycerol lipase-alpha | Homo sapiens (human) | 0.2677 | |
| Endothelial lipase | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM | 1 |
| Cimic, A; Cramer, SD; Eckel, RH; Gijón, MA; Glodé, LM; Pac, CT; Rider, L; Rodrigues, LU; Romero, L; Schlaepfer, IR; Sirintrapun, SJ | 1 |
3 other study(ies) available for etomoxir and orlistat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Carbohydrate Metabolism; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerulenin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epoxy Compounds; Fatty Acids; G1 Phase Cell Cycle Checkpoints; Glucose; Humans; Lactones; Lipid Metabolism; Multiple Myeloma; Orlistat; Oxidation-Reduction; Pyrazines; Retinoblastoma Protein | 2012 |
Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Enzyme Inhibitors; Epoxy Compounds; Humans; Hypoglycemic Agents; Lactones; Lipid Metabolism; Male; Metabolism; Mice; Mice, Nude; Orlistat; Oxidation-Reduction; Prostatic Neoplasms; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |